Format

Send to

Choose Destination
Genome Med. 2017 May 31;9(1):50. doi: 10.1186/s13073-017-0436-y.

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.

Author information

1
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
2
BC Children's Hospital, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
3
Immuneering Corporation, Cambridge, MA, USA.
4
Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel.
5
Teva Pharmaceutical Industries, Frazer, PA, USA.
6
Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel. Iris.Grossman@teva.co.il.

Abstract

BACKGROUND:

Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher response levels. The involvement of genes (e.g., HLA-DRB1*1501) with high inter-individual variability in Copaxone's mechanism of action (MoA) suggests the potential contribution of genetics to treatment response. This study aimed to identify genetic variants associated with Copaxone response in patient cohorts from late-phase clinical trials.

METHODS:

Single nucleotide polymorphisms (SNPs) associated with high and low levels of response to Copaxone were identified using genome-wide SNP data in a discovery cohort of 580 patients from two phase III clinical trials of Copaxone. Multivariable Bayesian modeling on the resulting SNPs in an expanded discovery cohort with 1171 patients identified a multi-SNP signature of Copaxone response. This signature was examined in 941 Copaxone-treated MS patients from seven independent late-phase trials of Copaxone and assessed for specificity to Copaxone in 310 Avonex-treated and 311 placebo-treated patients, also from late-phase trials.

RESULTS:

A four-SNP signature consisting of rs80191572 (in UVRAG), rs28724893 (in HLA-DQB2), rs1789084 (in MBP), and rs139890339 (in ZAK(CDCA7)) was identified as significantly associated with Copaxone response. Copaxone-treated signature-positive patients had a greater reduction in annualized relapse rate (ARR) compared to signature-negative patients in both discovery and independent cohorts, an effect not observed in Avonex-treated patients. Additionally, signature-positive placebo-treated cohorts did not show a reduction in ARR, demonstrating the predictive as opposed to prognostic nature of the signature. A 10% subset of patients, delineated by the signature, showed marked improvements across multiple clinical parameters, including ARR, MRI measures, and higher proportion with no evidence of disease activity (NEDA).

CONCLUSIONS:

This study is the largest pharmacogenetic study in MS reported to date. Gene regions underlying the four-SNP signature have been linked with pathways associated with either Copaxone's MoA or the pathophysiology of MS. The pronounced association of the four-SNP signature with clinical improvements in a ~10% subset of the MS patient population demonstrates the complex interplay of immune mechanisms and the individualized nature of response to Copaxone.

KEYWORDS:

Copaxone; Glatiramer acetate; Inter-individual variability; Multi-SNP signature; Multiple sclerosis; Multivariable Bayesian modeling; Pharmacogenetics; Treatment-response

PMID:
28569182
PMCID:
PMC5450152
DOI:
10.1186/s13073-017-0436-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center